Drawing on our executive search practice, we put this together to give employers a grounded, practical view they can act on. Onboarding a new MedTech executive is not a matter of orientation sessions and introductions, because the things a device company leader must absorb, the regulatory posture, the quality system, the clinical evidence base, the reimbursement position, take real time and cannot be picked up casually. A MedTech executive who is not properly onboarded into the regulatory and quality reality can make an early decision that costs the company far more than the onboarding effort would have.
Key Takeaways
- MedTech onboarding must cover regulatory, quality, and clinical context substantively.
- Early decisions made without that context can be costly to reverse.
- Give the executive access to the quality system and regulatory history.
- Structure the first 90 days around learning before major moves.
- Assign a credible internal guide, not just an HR checklist.
What a MedTech Executive Must Absorb
A new device company executive needs to understand things that do not appear in a standard onboarding pack: the regulatory status and history of the product portfolio, any open or past FDA findings, the state of the quality system and its known weaknesses, the clinical evidence supporting current claims, the reimbursement and coverage position, and the supplier and manufacturing constraints that limit change. These are the parameters within which every decision they make will operate. An executive who does not absorb them early will make plans that collide with reality, and in a regulated business that collision is expensive to undo.
Structure the First 90 Days Around Learning
The strongest MedTech onboarding sequences deliberately front-load learning and delay major moves. That means scheduled time with regulatory, quality, and clinical leadership; review of the quality system, inspection history, and open CAPAs; time with the commercial and market access teams on the reimbursement position; and site visits to manufacturing. Boards and CEOs sometimes push new executives to demonstrate impact quickly, but in device companies a leader who acts before understanding the regulatory and quality position is more likely to create problems than momentum. Protecting the learning period is a genuine investment.
Give Real Access, Not a Curated Version
Onboarding fails when the new executive is given a curated picture, the quality system as it is supposed to work rather than as it does, the regulatory history without the difficult episodes. Executives discover the reality eventually, usually at a worse moment, and the credibility cost of having been managed is significant. Give the new leader genuine access to inspection findings, open issues, known system weaknesses, and the parts of the clinical or reimbursement picture that are unresolved. Candor early builds both better decisions and the trust the relationship will need later.
Assign a Credible Internal Guide
A checklist does not transfer context; a person does. Pairing the new executive with a credible internal guide, often a respected regulatory, quality, or clinical leader, who can explain how things actually work, who the informal decision-makers are, and what the history behind current practices is, accelerates integration substantially. This is different from an HR buddy assignment; it should be someone with genuine standing whose explanations the new executive will trust. In a sector where context is technical and consequential, this relationship is often the single most valuable onboarding element.
What This Looks Like in Practice
A device company onboarding a C-suite hire schedules substantive time with regulatory, quality, clinical, and market access leadership, gives genuine access to inspection history, open CAPAs, and unresolved issues, structures the first 90 days around learning before major moves, and assigns a credible internal guide with real standing. It protects the learning period against pressure to show early impact. It does not run a generic orientation or present a curated version of the company.
The Mistake Employers Keep Making
The most common mistake is pressing a new MedTech executive to demonstrate impact within weeks, which pushes them to act before they understand the regulatory posture, quality system, and evidence base. The early decision that results, a manufacturing change, a claims push, a program reprioritization, then runs into constraints nobody explained, and undoing it costs far more than the learning period would have. The company mistakes early activity for early progress.
What MedTech Onboarding Must Cover
| Area | Why It Matters Early |
|---|---|
| Regulatory status and history | Sets the boundaries on every plan |
| Quality system and open CAPAs | Reveals real constraints and risks |
| Clinical evidence base | Determines what can be claimed |
| Reimbursement position | Shapes commercial reality |
| Manufacturing and supplier constraints | Limits how fast anything can change |
The Bottom Line
MedTech onboarding must transfer the regulatory, quality, clinical, and reimbursement context within which every decision operates, so give genuine access rather than a curated picture, structure the first 90 days around learning, and assign a credible internal guide, since an executive who acts before understanding these constraints creates problems that cost far more than the onboarding effort. Hire for the specific demands of the situation, and the rest of the leadership equation gets easier.
Related Reading
For more, see The Cost of a Bad Executive Hire in Medical Devices, How to Retain Executive Talent in the Medical Device Industry, What to Look for in a Head of Quality Systems (MedTech).
Frequently Asked Questions
- Q: What makes MedTech onboarding different?
- A: The new executive must absorb regulatory status, quality system realities, clinical evidence, and reimbursement position, technical context that sets the boundaries on every decision they will make.
- Q: How long should the learning period be?
- A: Typically the first 90 days should be weighted toward learning before major moves, since acting before understanding the regulatory and quality position tends to create costly problems.
- Q: Should we share problems with a new executive?
- A: Yes; give genuine access to inspection findings, open CAPAs, and unresolved issues, since a curated picture damages credibility and produces worse decisions.
- Q: What is the most valuable onboarding element?
- A: Often a credible internal guide with real standing, a respected regulatory, quality, or clinical leader who can transfer context a checklist cannot.
- Q: What is the common onboarding mistake?
- A: Pressing for early impact, which pushes the executive to act before understanding constraints, producing decisions that cost more to undo than the learning period would have taken.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
